MX2021006957A - Usos de la medicion de la velocidad de filtracion glomerular transdermica en terapia continua de reemplazo renal. - Google Patents

Usos de la medicion de la velocidad de filtracion glomerular transdermica en terapia continua de reemplazo renal.

Info

Publication number
MX2021006957A
MX2021006957A MX2021006957A MX2021006957A MX2021006957A MX 2021006957 A MX2021006957 A MX 2021006957A MX 2021006957 A MX2021006957 A MX 2021006957A MX 2021006957 A MX2021006957 A MX 2021006957A MX 2021006957 A MX2021006957 A MX 2021006957A
Authority
MX
Mexico
Prior art keywords
patient
fluorescent agent
medicament
transdermal
rate measurement
Prior art date
Application number
MX2021006957A
Other languages
English (en)
Inventor
Richard B Dorshow
Stuart L Goldstein
Original Assignee
Medibeacon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medibeacon Inc filed Critical Medibeacon Inc
Publication of MX2021006957A publication Critical patent/MX2021006957A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14525—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using microdialysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • A61B5/14556—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases by fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
    • A61B5/201—Assessing renal or kidney functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule

Abstract

Se describe en la presente un método para determinar una prescripción de dosificación para un medicamento en un paciente que se somete a CRRT. El método incluye en general administrar al torrente sanguíneo del paciente un agente fluorescente; administrar al paciente al menos una dosis del medicamento; llevar a cabo la CRRT en el paciente después de administrar el agente fluorescente al paciente; exponer el agente fluorescente a luz visible o infrarroja; monitorear transcutáneamente un cambio en la energía espectral del agente fluorescente durante un período de tiempo; correlacionar un cambio en la intensidad de la energía espectral del agente fluorescente a una velocidad de depuración del agente fluorescente del torrente sanguíneo en el paciente; calcular una velocidad de depuración del medicamento en el paciente; determinar una cantidad del medicamento en el torrente sanguíneo del paciente como una función de tiempo; y ajustar una prescripción de dosificación del medicamento al paciente.
MX2021006957A 2018-12-12 2019-08-27 Usos de la medicion de la velocidad de filtracion glomerular transdermica en terapia continua de reemplazo renal. MX2021006957A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778334P 2018-12-12 2018-12-12
PCT/US2019/048329 WO2020122998A1 (en) 2018-12-12 2019-08-27 Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy

Publications (1)

Publication Number Publication Date
MX2021006957A true MX2021006957A (es) 2021-07-15

Family

ID=71071406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006957A MX2021006957A (es) 2018-12-12 2019-08-27 Usos de la medicion de la velocidad de filtracion glomerular transdermica en terapia continua de reemplazo renal.

Country Status (13)

Country Link
US (1) US20200187838A1 (es)
EP (1) EP3893848A4 (es)
JP (1) JP2022513195A (es)
KR (1) KR20210102371A (es)
CN (1) CN111298136A (es)
AU (1) AU2019397144A1 (es)
BR (1) BR112021011183A2 (es)
CA (1) CA3122681A1 (es)
IL (1) IL283855A (es)
MX (1) MX2021006957A (es)
PH (1) PH12021551362A1 (es)
SG (1) SG11202106309QA (es)
WO (1) WO2020122998A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133194B2 (en) * 2006-02-22 2012-03-13 Henry Ford Health System System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits
CN101351454A (zh) * 2006-06-22 2009-01-21 马林克罗特公司 吡嗪衍生物及其在肾脏监测中的用途
WO2010048347A2 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2013202655B2 (en) * 2008-10-21 2015-06-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RS60001B1 (sr) * 2011-04-21 2020-04-30 Bayer Ip Gmbh Pripremanje gadobutrola visoke čistoće
US11077211B2 (en) * 2013-11-11 2021-08-03 Medibeacon Inc. Compositions and methods for assessing gut function
EP3294296A4 (en) * 2015-05-12 2018-12-26 Medibeacon Inc. Compositions and methods for assessing eye vasculature
KR20230054506A (ko) * 2017-10-27 2023-04-24 메디비콘 아이엔씨. 신장 기능 측정을 위한 조성물 및 시스템
AU2018354391C1 (en) * 2017-10-27 2021-01-21 Medibeacon Inc. Methods for renal function determination

Also Published As

Publication number Publication date
CN111298136A (zh) 2020-06-19
JP2022513195A (ja) 2022-02-07
SG11202106309QA (en) 2021-07-29
BR112021011183A2 (pt) 2021-08-24
PH12021551362A1 (en) 2021-11-29
IL283855A (en) 2021-07-29
US20200187838A1 (en) 2020-06-18
CA3122681A1 (en) 2020-06-18
EP3893848A4 (en) 2022-12-14
AU2019397144A1 (en) 2021-07-01
EP3893848A1 (en) 2021-10-20
KR20210102371A (ko) 2021-08-19
WO2020122998A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MX2023004722A (es) Nebulizador inteligente.
AU2021257754B2 (en) LSD dose identification
MX2021009623A (es) Respuesta dependiente del genotipo y de la dosis a un inhibidor de transporte de ácidos biliares dependiente de sodio apical (asbti) en pacientes con deficiencia en la bomba de exportación de sales biliares.
BR112016028964A2 (pt) métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
MX2015007714A (es) Agente terapeutico de direccionamiento a glipicano 3 (gpc3) que es administrado a pacientes para quienes la terapia con agentes terapeuticos de direccionamiento a gpc3 es eficaz.
BR112014018429A8 (pt) Método para tratar um paciente que sofre de não-24, e, método para o tratamento crônico de não-24 em uma pessoa que está totalmente cega
MX2019006900A (es) Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno.
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
BR112021026369A2 (pt) Derivados de 2h-indazol e seu uso no tratamento de doenças
MX2022004258A (es) Entrega transdermica de cannabidiol.
WO2013010015A3 (en) Combination als therapy
EA201992658A1 (ru) Методы лечения рекуррентной глиобластомы (rgbm)
Green Brain injury as a neurodegenerative disorder
BR112017011663A2 (pt) dispensador de insulina, método de controle dos níveis de glicose em um paciente, e, sistema.
PH12021551362A1 (en) Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy
WO2010088375A3 (en) Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
DE602004022968D1 (de) Ie behandlung mti insulinsensibilisatoren
Costa-Scharplatz et al. Cost-effectiveness of secukinumab compared to ustekinumab in patients with psoriasis from a Swedish health care perspective
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
Montaudié et al. Solar urticaria to visible light triggered by light-emitting diode therapy